Wuxi Bio's first half of 2026 revenue grew 18% year-on-year to CNY 11.7 billion, driven by 169 new projects, while operating margin expanded 450 basis points from lower overhead and more biosimilar projects, which yield greater pricing due to their molecular complexity.
The Biosecure Act is repealed or becomes irrelevant, leading to more pipeline projects in North America.
The Biosecure Act forces WuXi to abandon US contracts in its pipeline.
|
Metric
|
02269
|
IQV
|
CRL
|
|---|---|---|---|
Price/Earnings (Normalized) | 35.59 | 20.91 | 28.97 |
Price/Book Value | 4.35 | 6.95 | 4.82 |
Price/Sales | 8.87 | 2.61 | 3.50 |
Price/Cash Flow | 24.07 | 16.94 | 20.40 |
|
Metric
|
02269
|
IQV
|
CRL
|
|---|---|---|---|
Quick Ratio | 2.64 | 0.62 | 0.80 |
Current Ratio | 3.32 | 0.71 | 1.35 |
Interest Coverage | 67.52 | 2.99 | −0.77 |
|
Metric
|
02269
|
IQV
|
CRL
|
|---|---|---|---|
Return on Assets (Normalized) | 10.38% | 7.22% | 6.50% |
Return on Equity (Normalized) | 14.65% | 34.41% | 15.51% |
Return on Invested Capital (Normalized) | 11.25% | 12.37% | 9.46% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|dpzW$@! | LOCK|zN!%L | $128B | |||
| Moderna Inc
MRNA
| LOCK|w>#lqm | LOCK|Z% | $76B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|%M$<d<^ | LOCK|RghZ | $76B | |||
| argenx SE ADR
ARGX
| LOCK|<#<T&r | LOCK|#L | $57B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|<%^Px$ | LOCK|MST | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|>m&$gV | LOCK|!>%w | $29B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|^C#?NNS | LOCK|RB%% | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|>zvl@> | LOCK|!? | $24B | |||
| Incyte Corp
INCY
| LOCK|!>%d!G^ | LOCK|D% | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|f$sJ?! | LOCK|x! | $15B |
United States